If you have been reading about MC4 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
== Structural studies == As of late 2007, 8 structures have been solved for this class of enzymes, with PDB accession codes PDB: 2AFM, PDB: 2AFO, PDB: 2AFS, PDB: 2AFU, PDB: 2AFW, PDB: 2AFX, PDB: 2AFZ, and PDB: 2IWA.
Acquired progressive lymphangioma (benign lymphangioendothelioma) Acral fibrokeratoma (acquired digital fibrokeratoma, acquired periungual fibrokeratoma) Acrochordon (cutaneous papilloma, cutaneous tag, fibroepithelial polyp, fibroma molluscum, fibroma pendulum, papilloma colli, skin tag, soft fibroma, Templeton skin tag) Adenoma sebaceum Adult type of generalized eruption of cutaneous mastocytosis African cutaneous Kaposi sarcoma African lymphadenopathic Kaposi sarcoma Aggressive infantile fibromatosis AIDS-associated Kaposi sarcoma Ainhum (bankokerend, dactylolysis spontanea, sukhapakla) Angiofibroma Angiokeratoma Angiokeratoma of Fordyce (angiokeratoma of the scrotum and vulva) Angiokeratoma of Mibelli (Mibelli's angiokeratoma, telangiectatic warts) Angioleiomyoma (vascular leiomyoma) Angiolipoleiomyoma Angiolipoma Angioma serpiginosum Angiosarcoma Aponeurotic fibroma (calcifying aponeurotic fibroma, juvenile aponeurotic fibroma) Atypical fibroxanthoma Benign lipoblastomatosis (embryonic lipoma) Buschke–Ollendorff syndrome (dermatofibrosis lenticularis disseminata) Capillary aneurysms Carcinoid Cellular angiofibroma Cherry angioma (De Morgan spot, senile angioma) Chondrodermatitis nodularis chronica helicis (chondrodermatitis nodularis helicis) Chondroid lipoma Chordoma Classic Kaposi sarcoma Collagenous fibroma (desmoplastic fibroblastoma) Composite hemangioendothelioma Connective tissue nevus (collagenoma, elastoma, shagreen patch) Cutaneous endometriosis Cutaneous meningioma (heterotopic meningeal tissue, rudimentary meningocele) Cutaneous myelofibrosis Cutaneous myxoma Cutis marmorata telangiectatica congenita (congenital generalized phlebectasia, Van Lohuizen syndrome) Dermal dendrocyte hamartoma Dermatofibroma (benign fibrous histiocytoma, dermal dendrocytoma, fibrous dermatofibroma, fibrous histiocytoma, fibroma simplex, histiocytoma, nodular subepidermal fibrosis, sclerosing hemangioma) Dermatofibrosarcoma protuberans Desmoid tumor Diffuse cutaneous mastocytosis Diffuse infantile fibromatosis Dupuytren's contracture (Dupuytren's diathesis, Dupuytren's disease, palmar fibromatosis) Eccrine angiomatous hamartoma Elastofibroma dorsi Endovascular papillary angioendothelioma (Dabska tumor, Dabska-type hemangioendothelioma, hobnail hemangioendothelioma, malignant endovascular papillary angioendothelioma, papillary intralymphatic angioendothelioma) Epithelioid cell histiocytoma Epithelioid hemangioendothelioma Epithelioid sarcoma Erythrodermic mastocytosis Extraskeletal chondroma (chondroma of soft parts) Familial myxovascular fibromas Fascial hernia Fibroma of tendon sheath Fibromatosis colli (sternomastoid tumor of infancy) Fibrous hamartoma of infancy Fibrous papule of the nose (benign solitary fibrous papule, fibrous papule of the face) Folded skin with scarring (Michelin tire baby syndrome) Fordyce's spot (Fordyce's disease) Ganglion cyst Ganglioneuroma Gardner fibroma Genital leiomyoma (dartoic leiomyoma) Giant cell fibroblastoma Giant cell tumor of the tendon sheath (giant cell synovioma, localized nodular tenosynovitis, pigmented villonodular synovitis) Glomeruloid hemangioma Glomus tumor (glomangioma, solid glomus tumor, solitary glomus tumor) Granular cell tumor (Abrikossoff's tumor, Abrikossov's tumor, granular cell myoblastoma, granular cell nerve sheath tumor, granular cell schwannoma) Hamartoma Hemangiopericytoma Hemangiosarcoma Hibernoma (fetal lipoma, lipoma of embryonic fat, lipoma of immature adipose tissue) Hypertrophic scar Immunosuppression-associated Kaposi sarcoma Infantile digital fibromatosis (inclusion body fibromatosis, infantile digital myofibroblastoma, Reye tumor) Infantile hemangiopericytoma (congenital hemangiopericytoma) Infantile myofibromatosis (congenital generalized fibromatosis, congenital multicentric fibromatosis) Infantile systemic hyalinosis (juvenile systemic hyalinosis) Intradermal spindle cell lipoma Intravascular papillary endothelial hyperplasia (Masson's hemangio-endotheliome vegetant intravasculaire, Masson's lesion, Masson's pseudoangiosarcoma, Masson's tumor, papillary endothelial hyperplasia) Juvenile hyaline fibromatosis (fibromatosis hyalinica multiplex juvenilis, Murray–Puretic–Drescher syndrome) Kaposiform hemangioendothelioma (infantile kaposiform hemangioendothelioma) Kasabach–Merritt syndrome (hemangioma with thrombocytopenia) Keloid (Keloidal scar) Keratinizing metaplasia Keratocyst Klippel–Trenaunay syndrome (angioosteohypertrophy syndrome, hemangiectatic hypertrophy) Knuckle pads (heloderma) Leiomyosarcoma Lipoma Liposarcoma (atypical lipoma, atypical lipomatous tumor) Lymphangiectasis (lymphangioma) Lymphangiomatosis Malignant fibrous histiocytoma Malignant peripheral nerve sheath tumor (malignant schwannoma, neurofibrosarcoma, neurosarcoma) Mast cell sarcoma Meningocele Metastatic carcinoma Microvenular hemangioma (microcapillary hemangioma) Midline nevus flammeus (angel's kiss, salmon patch) Multifocal lymphangioendotheliomatosis (congenital cutaneovisceral angiomatosis with thrombocytopenia, multifocal lymphangioendotheliomatosis with thrombocytopenia) Multinucleate cell angiohistocytoma Multiple cutaneous and uterine leiomyomatosis syndrome (leiomyomatosis cutis et uteri, multiple leiomyomatosis, Reed's syndrome) Multiple cutaneous leiomyoma (pilar leiomyoma) Neural fibrolipoma Neuroblastoma (infantile neuroblastoma, neuroepithelioma) Neuroma cutis Neurothekeoma (bizarre cutaneous neurofibroma, cutaneous lobular neuromyxoma, myxoma of the nerve sheath, myxomatous perineurioma, nerve sheath myxoma) Nevus flammeus (capillary malformation, port-wine stain) Nevus flammeus nuchae (stork bite) Nevus lipomatosus superficialis (nevus lipomatosis of Hoffman and Zurhelle) Nevus oligemicus Nodular fasciitis (nodular pseudosarcomatous fasciits, pseudosarcomatous fasciitis, subcutaneous pseudosarcomatous fibromatosis) Oral submucous fibrosis Pachydermodactyly Palisaded encapsulated neuroma Paraneoplastic syndrome Pearly penile papules (hirsuties coronae glandis, hirsutoid papillomas) Peyronie's disease (induratio penis plastica) Phakomatosis pigmentovascularis Piloleiomyoma Plantar fibromatosis (Ledderhose's disease) Pleomorphic fibroma Pleomorphic lipoma Plexiform fibrohistiocytic tumor Porokeratotic eccrine ostial and dermal duct nevus Progressive nodular histiocytoma Proliferating angioendotheliomatosis Prominent inferior labial artery Pseudo-ainhum
Erectile dysfunction (ED), also referred to as impotence, is a form of sexual dysfunction in males characterized by the persistent or recurring inability to achieve or maintain a penile erection with sufficient rigidity and duration for satisfactory sexual activity. It is the most common sexual problem in males and can cause psychological distress due to its impact on self-image and sexual relationships. The term erectile dysfunction does not encompass other erection-related disorders, such as priapism. The majority of ED cases are attributed to physical risk factors and predictive factors. These factors can be categorized as vascular, neurological, local penile, hormonal, and drug-induced. Notable predictors of ED include aging, cardiovascular disease, diabetes mellitus, high blood pressure, obesity, abnormal lipid levels in the blood, hypogonadism, smoking, depression, and medication use. Approximately 10% of cases are linked to psychosocial factors, encompassing conditions such as depression, stress, and problems within relationships. ED is reported in 18% of males aged 50 to 59 years, and 37% in males aged 70 to 75. Treatment of ED encompasses addressing the underlying causes, lifestyle modification, and addressing psychosocial issues. In many instances, medication-based therapies are used, specifically PDE5 inhibitors such as sildenafil. These drugs function by dilating blood vessels, facilitating increased blood flow into the spongy tissue of the penis, analogous to opening a valve wider to enhance water flow in a fire hose.
Sources: en.wikipedia.org
=== Bacteria === Some bacteria have been shown to be able to turn morphine into closely related drugs, including hydromorphone and dihydromorphine among others. The bacterium Pseudomonas putida serotype M10 produces a naturally occurring NADH-dependent morphinone reductase that can work on unsaturated 7,8 bonds, with result that, when these bacteria are living in an aqueous solution containing morphine, significant amounts of hydromorphone form, as it is an intermediary metabolite in this process; the same goes for codeine being turned into hydrocodone.
== Research == 1999: Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7. 2001, June: Results from ARMADA, a double-blind, placebo-controlled clinical trial involving 271 patients with active rheumatoid arthritis, despite treatment with methotrexate, are announced. Results show that 50% of patients demonstrate a 50% improvement in their American College of Rheumatology (ACR) score. 2002: Broke ground on a new biologics manufacturing facility. 2002: Adalimumab results from five separate trials show that it is effective at reducing signs and symptoms of rheumatoid arthritis, with rapid onset of action and sustained efficacy. Adalimumab was safe and effective when given alone or in combination with methotrexate (MTX) as a subcutaneous injection. 2002: Humira approved by the US Food and Drug Administration (FDA) for treatment of rheumatoid arthritis. 2003: Humira made available for the treatment of rheumatoid arthritis and continued clinical studies for additional indications. 2005: Humira made available for the treatment of psoriatic arthritis. Exceeded US$1 billion in annual sales for the first time. 2005: Japanese company Eisai submits new drug application to make adalimumab (D2E7) available for the treatment of rheumatoid arthritis in Japan. 2006: Submitted Humira for approval for the treatment of Crohn's disease. Approved for the treatment of ankylosing spondylitis. Exceeded US$2 billion in annual sales. 2007: Humira approved for the treatment of Crohn's disease in the United States.
persons and nationals." On March 6, 2026, Anthropic's CEO Dario Amodei stated that his company will challenge the DoD in court. Anthropic's partners, including Microsoft, Amazon and Google stated their agreement with Amodei. On March 8, 2026, OpenAI (the parent company of ChatGPT) announced that their head of robotics, Caitlin Kalinowski, had resigned stating, "surveillance of Americans without judicial oversight and lethal autonomy without human authorization are lines that deserved more deliberation than they got."
Taylor (2015) reported that the perceived self-efficacy and perceived helplessness subscales tended to estimate scores reliably across levels of the latent variables except among respondents with exceptionally low levels of perceived helplessness and exceptionally high levels of perceived self-efficacy. Finally, much less is known about the reliability of scores from the 4-item form.
Sources: en.wikipedia.org
Investigators nationwide may compete for pilot funding and access to the Center's specialized cores, fostering new collaborations and expanding the national aging research community. These activities complement the Barshop Institute's NIH-funded Biology of Aging Training Program (T32), creating a rich educational environment for predoctoral students, postdoctoral fellows, and junior faculty.
When the IBD column compared to recently established PNIPAAm columns, electrostatic forces show remarkably higher retention ability of charged compounds than its hydrophilic predecessor. A single stationary phase can accomplish pharmaceutical separations based on hydrophobic interactions, hydrophilic interactions, and electrostatic interactions merely by adjusting the temperature (while adjusting pH to tweak the LCST).
== Biosynthesis == Pancreatic elastase is formed by activation of proelastase from mammalian pancreas by trypsin. After processing to proelastase, it is stored in the zymogen granules and then activated to elastase in the duodenum by the tryptic cleavage of a peptide bond in the inactive form of the precursor molecule. This process results in the removal of an activation peptide from the N-terminal, that enables the enzyme to adopt its native conformation.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.